| Literature DB >> 31819553 |
Ping Mao1,2, Ping Peng1, Zhiyong Liu3, Zhenrui Xue1, Chunyan Yao1.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is a common pathogen of hospital infection with multi-drug resistant characteristics. Its spread and epidemic pose great challenges to nosocomial infection control. This study was aimed to identify risk factors for hospital-acquired MRSA (HA-MRSA) infections and investigate its clinical outcome, developing infection control strategies and improving patient outcomes.Entities:
Keywords: HA-MRSA; MSSA; clinical outcomes; risk factors
Year: 2019 PMID: 31819553 PMCID: PMC6885554 DOI: 10.2147/IDR.S223536
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Comparison Of Infection Types Among The Three Groups
| Infection Type | MRSA | MSSA | Control |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Wound and soft tissue infections | 155 (61.8%) | 218 (64.3%) | 193 (64.3%) |
| Respiratory tract infection | 51 (20.3%) | 79 (23.3%) | 56 (18.7%) |
| Bloodstream infection | 24 (9.6%) | 14 (4.1%) | 16 (5.3%) |
| Intra-abdominal infection | 8 (3.2%) | 5 (1.5%) | 9 (3.0%) |
| Others | 13 (5.2%) | 23 (6.8%) | 26 (8.7%) |
| Total | 251 (100%) | 339 (100%) | 300 (100%) |
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus strains.
Univariate Prediction Of Risk Factors For MRSA And MSSA Infection
| Variable | No.(%) Of Patients | MRSA VS CON | MSSA VS CON | ||||
|---|---|---|---|---|---|---|---|
| MRSA (n=251) | MSSA (n=339) | CON (n=300) | P-value | OR (95% CI) | P-value | OR (95% CI) | |
| Demographic | |||||||
| Age, year, mean±SD | 48.42±16.039 | 49.54±15.345 | 50.30±14.462 | 0.149 | (-) | 0.522 | (-) |
| Male sex | 176 (70.1) | 235 (69.3) | 222 (74.0) | 0.311 | 0.825 (0.567–1.198) | 0.191 | 0.794 (0.562–1.122) |
| Underlying disease | |||||||
| Diabetes mellitus | 37 (14.7) | 46 (13.6) | 44 (14.7) | 0.980 | 1.006(0.627—1.615) | 0.691 | 0.913 (0.585–1.427) |
| Malignancy | 30 (12.0) | 38 (11.2) | 24 (8.0) | 0.122 | 1.561 (0.887–2.747) | 0.173 | 1.452 (0.849–2.483) |
| Inflammatory disease | 27 (10.8) | 42 (12.4) | 22 (7.3) | 0.162 | 1.523 (0.844–2.747) | 0.036 | 1.787 (1.040–3.070) |
| Hypertension | 32 (12.7) | 58 (17.1) | 53 (17.7) | 0.113 | 0.681 (0.423–1.095) | 0.853 | 0.962 (0.639–1.449) |
| Renal disease | 22 (8.8) | 38(11.2) | 27 (9.0) | 0.923 | 0.971 (0.539–1.752) | 0.357 | 1.276 (0.759–2.147) |
| Cardiovascular disease | 28 (11.2) | 21 (6.2) | 24 (8.0) | 0.209 | 1.444 (0.814–2.561) | 0.375 | 0.759 (0.414–1.394) |
| Tuberculosis | 5 (2.0) | 6 (1.8) | 4 (1.3) | 0.546 | 1.504 (0.400–5.662) | 0.658 | 1.333 (0.373–4.771) |
| Hematonosis | 3 (1.2) | 2 (0.6) | 1 (0.3) | 0.267 | 3.617(0.374–34.990) | 0.640 | 1.744 (0.160–19.688) |
| Unhealthy lifestyle | |||||||
| Smoking history | 78 (31.1) | 83 (24.5) | 81 (27.0) | 0.293 | 1.219 (0.843–1.764) | 0.468 | 0.877 (0.614–1.251) |
| Alcohol abuse | 21 (8.4) | 35 (10.3) | 19 (6.3) | 0.361 | 1.350 (0.709–2.573) | 0.073 | 1.703 (0.952–3.046) |
| Invasive procedure | |||||||
| Endoscopic therapy | 8 (3.2) | 7 (2.1) | 9 (3.0) | 0.899 | 1.064 (0.405–2.801) | 0.453 | 0.682 (0.251–1.853) |
| Presence of a Foley catheter | 141 (56.2) | 132 (38.9) | 134 (44.7) | 0.007 | 1.588 (1.133–2.226) | 0.143 | 0.790 (0.576–1.083) |
| Presence of central venous catheters | 43 (17.1) | 37 (10.9) | 22 (7.3) | 0.001 | 2.612 (1.516–4.502) | 0.121 | 1.548 (0.891–2.689) |
| Insertion of gastric tube | 24 (9.6) | 16 (4.7) | 23 (7.7) | 0.428 | 1.273 (0.700–2.316) | 0.124 | 0.597 (0.309–1.152) |
| Tracheotomy | 31 (12.4) | 36 (10.6) | 25 (8.3) | 0.120 | 1.550 (0.889–2.702) | 0.327 | 1.307 (0.765–2.233) |
| Sputum suction | 51 (20.3) | 33 (9.7) | 19 (6.3) | 0.000 | 3.771 (2.160–6.583) | 0.119 | 1.595 (0.887–2.869) |
| Types of antibiotics used (1–2) | 179 (71.3) | 227 (67.0) | 198 (66.0) | 0.182 | 1.281 (0.891–1.841) | 0.797 | 1.044 (0.751–1.451) |
| Types of antibiotics used (≥3) | 51 (20.3) | 65 (19.2) | 49 (16.3) | 0.228 | 1.306 (0.846–2.016) | 0.350 | 1.215 (0.808–1.828) |
| Blood examination | |||||||
| Serum albumin | |||||||
| <35 g/L | 132 (52.6) | 198 (58.4) | 175 (58.3) | 0.176 | 0.792 (0.565–1.111) | 0.985 | 1.003 (0.732–1.375) |
| (35–51)g/L | 114 (45.4) | 135 (39.8) | 116 (38.7) | 0.109 | 1.320 (0.939–1.855) | 0.765 | 1.050 (0.764–1.443) |
| >51 g/L | 5 (2.0) | 6 (1.8) | 9 (3.0) | 0.454 | 0.657 (0.217–1.987) | 0.305 | 0.583 (0.205–1.656) |
| White blood cell | |||||||
| <4.0×10^9/L | 15 (6.0) | 24 (7.1) | 23 (7.7) | 0.435 | 0.765 (0.390–1.501) | 0.777 | 0.923 (0.533–1.601) |
| (4.0–10.0)×10^9/L | 27 (10.8) | 34 (10.0) | 42 (14.0) | 0.252 | 0.740 (0.442–1.240) | 0.122 | 0.685 (0.423–1.108) |
| >10.0×10^9/L | 209 (83.3) | 281 (82.9) | 235 (78.3) | 0.145 | 1.376 (0.895–2.117) | 0.145 | 1058 (0.980–1.143) |
| Others | |||||||
| Receipt of immunosuppressors | 24 (9.6) | 56 (16.5) | 37 (12.3) | 0.303 | 0.752 (0.436–1.294) | 0.135 | 1.407 (0.899–2.201) |
| Surgery | 178 (70.9) | 227 (67.0) | 199 (66.3) | 0.249 | 1.238 (0.861–1.779) | 0.866 | 1.029 (0.740–1.430) |
| Total hospital stays more than 30 days | 114 (45.4) | 56 (16.5) | 56 (18.7) | 0.000 | 3.626 (2.474–5.313) | 0.476 | 0.862 (0.573–1.297) |
| Hospital stays before positive culture more than 15 days | 29 (11.6) | 24 (7.1) | 20 (6.7) | 0.047 | 1.829 (1.007–3.320) | 0.837 | 1.067 (0.577–1.973) |
| Chemotherapy | 18 (7.2) | 16 (4.7) | 12 (4.0) | 0.107 | 1.854 (0.875–3.927) | 0.658 | 1.189 (0.553–2.555) |
| Radiotherapy | 13 (5.2) | 11 (3.2) | 8 (2.7) | 0.132 | 1.994 (0.813–4.890) | 0.668 | 1.224 (0.486–3.085) |
| Admission to the ICU | 53 (21.1) | 68 (20.1) | 70 (23.3) | 0.534 | 0.880 (0.587–1.318) | 0.316 | 0.824 (0.565–1.202) |
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus strains; CON, control group.
Multivariate Analysis Of Risk Factors For MRSA And MSSA Infection
| Variable | MRSA VS CON | MSSA VS CON | ||
|---|---|---|---|---|
| P-value | OR (95% CI) | P-value | OR (95% CI) | |
| Presence of central venous catheters | 0.028 | 1.932 (1.074–3.477) | ||
| Sputum suction | 0.000 | 2.887 (1.591–5.240) | ||
| Total hospital stays more than 30 days | 0.000 | 3.067 (2.063–4.559) | ||
| Inflammatory disease | 0.030 | 1.820 (1.058–3.131) | ||
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus strains; CON, control group.
Comparison Of Clinical Outcomes Among The Three Groups
| Clinical Outcomes | No.(%) Of Patients | MRSA VS CON | MRSA VS MSSA | ||
|---|---|---|---|---|---|
| MRSA (251) | MSSA (339) | CON (300) | P-value | P-value | |
| Total hospital stays more than 30 days | 114 (45.4) | 56 (16.5) | 56 (18.7) | 0.000 | 0.000 |
| Admission to the ICU | 53 (21.1) | 50 (14.7) | 43 (14.3) | 0.037 | 0.044 |
| In-hospital mortality | 43 (17.1) | 45 (13.3) | 38 (12.7) | 0.140 | 0.194 |
| Poor prognosis | 69 (27.5) | 58 (17.1) | 48 (16.0) | 0.001 | 0.002 |
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus strains; CON, control group.
Univariate Analysis Of Predictors For Poor Prognosis In The MRSA Group
| Variable | No. (%) Of Patients | P-value | |
|---|---|---|---|
| Poor Prognosis (69) | Good Prognosis (182) | ||
| Demographic | |||
| Age, year, mean±SD | 50.52±17.06 | 47.90±15.55 | 0.246 |
| Male sex | 45 (65.2) | 131 (72.0) | 0.296 |
| Underlying disease | |||
| Diabetes mellitus | 11 (15.9) | 26 (14.3) | 0.741 |
| Malignancy | 12 (17.4) | 18 (9.9) | 0.102 |
| Inflammatory disease | 7 (10.1) | 20 (11.0) | 0.847 |
| Hypertension | 10 (14.5) | 22 (12.1) | 0.610 |
| Renal insufficiency | 11 (15.9) | 11 (6.0) | 0.013 |
| Cardiac insufficiency | 10 (14.5) | 18 (9.9) | 0.301 |
| Tuberculosis | 2 (2.9) | 3 (1.6) | 0.899 |
| Hematopathy | 1 (1.4) | 2 (1.1) | 1.000 |
| Unhealth lifestyle | |||
| Smoking history | 18 (26.1) | 60 (33.0) | 0.293 |
| Alcohol abuse | 7 (10.1) | 14 (7.7) | 0.531 |
| Invasive procedure | |||
| Endoscopic therapy | 4 (5.8) | 4 (2.2) | 0.295 |
| Presence of a Foley catheter | 42 (60.9) | 99 (54.4) | 0.356 |
| Presence of central venous catheters | 18 (26.1) | 25 (13.7) | 0.020 |
| Insertion of gastric tube | 11 (15.9) | 13 (7.1) | 0.034 |
| Tracheotomy | 9 (13.0) | 22 (12.1) | 0.837 |
| Sputum suction | 18 (26.1) | 33 (18.1) | 0.162 |
| Antibiotic use | |||
| Empirical use of antibiotics | 36 (52.2) | 122 (67.0) | 0.030 |
| Use antibiotics based on drug susceptibility test | 48 (69.6) | 118 (64.8) | 0.480 |
| Antibiotic us more than 15 days | 28 (40.6) | 77 (42.3) | 0.804 |
| Blood examination | |||
| Serum albumin | |||
| <35 g/L | 41 (59.4) | 91 (50.0) | 0.182 |
| (35–51)g/L | 26 (37.7) | 88 (48.4) | 0.130 |
| >51 g/L | 2 (2.9) | 3 (1.6) | 0.899 |
| White blood cell | |||
| <4.0×10^9/L | 2(2.9) | 13(7.1) | 0.333 |
| (4.0–10.0)×10^9/L | 8(11.6) | 19(10.4) | 0.792 |
| >10.0×10^9/L | 59 (85.5) | 150 (82.4) | 0.558 |
| Others | |||
| Receipt of immunosuppressors | 12 (17.4) | 12 (6.6) | 0.009 |
| Surgery | 54 (78.3) | 124 (68.1) | 0.115 |
| Total hospital stays more than 30 days | 31 (44.9) | 83 (45.6) | 0.923 |
| Chemotherapy | 5(7.2) | 13 (7.1) | 0.977 |
| Radiotherapy | 4 (5.8) | 9 (4.9) | 1.000 |
| Admission to ICU | 17 (24.6) | 36 (19.8) | 0.400 |
| Infection type | |||
| Wound and soft tissue infections | 37 (53.6) | 119 (64.8) | 0.103 |
| Respiratory tract infection | 18 (26.1) | 33 (18.1) | 0.162 |
| Bloodstream infection | 7 (10.1) | 17 (9.3) | 0.847 |
| Intra-abdominal infection | 5 (7.2) | 3 (1.6) | 0.064 |
| Others | 1 (1.4) | 12 (6.6) | 0.186 |
Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.
Multivariate Analysis Of Factors Associated With Poor Prognosis In MRSA Group
| Variate | Good Prognosis VS Poor Prognosis | |
|---|---|---|
| P-value | OR (95% CI) | |
| Renal insufficiency | 0.032 | 2.744 (1.089–6.914) |
| Receipt of immunosuppressors | 0.012 | 3.140 (1.284–7.678) |
| Empirical use of antibiotics | 0.029 | 0.514 (0.282–0.935) |
Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.